本报讯 （记者朱宝琛）为深入贯彻中国证监会及北京市相关工作部署，做好科技金融大文章，提升金 融支持科技创新质效，服务北京国际科技创新中心建设，8月15日，北京证监局、中国人民银行北京市 分行、北京市科学技术委员会、中关村科技园区管理委员会与北京基金小镇共同举办"中关村科技·金融 汇"第6期投贷联动融资对接活动。 北京证监局私募处处长在主持发言中介绍了北京辖区股权创业投资机构、科技型企业和银行投融资方面 的现实需求和结合点，推动投贷联动融资对接的原则和意义，表示将与各委办局合力搭建具有北京特色 创新性的供需对接平台，围绕首都高精尖产业结构、科创型企业成长周期提供更优质、高效的服务；人 民银行北京市分行负责人介绍了投贷联动平台建设和支持私募基金、科创企业发展方面的情况，以及前 期投贷联动融资对接取得的积极成效；北京基金小镇相关负责人介绍了小镇私募机构发展情况，服务实 体经济情况，以及小镇在服务和引导管理人合规展业方面开展的风险防控、合规培训等方面的做法和成 效。 本次活动聚焦"投贷联动"，为科技型企业搭建股权融资与债权融资高效对接的"桥梁"，臻知医学、星川 新能源、平方和、东方空间、华龛生物、泰科天润、大橡科技等 ...

Core Viewpoint - The launch of three service platforms in the IC PARK aims to address the testing shortcomings in the integrated circuit field in Beijing and the surrounding Jing-Jin-Ji region, enhancing the efficiency of chip design and development processes [1] Group 1: Service Platforms - The three newly launched service platforms include a high-speed signal testing laboratory, a high-end advanced packaging technology service center, and a power cycling and transient thermal testing laboratory, all focusing on common technologies in the chip sector [1] - The high-speed signal testing laboratory specifically targets applications in satellite communication, automotive navigation, and data center high-speed interconnects, making it one of the few laboratories in the market with systematic testing capabilities [1] Group 2: Industry Impact - The increasing data volume and the corresponding demand for faster chip data processing speeds highlight the importance of testing chip information transmission speeds during the research and development process [1] - Previously, many small and medium-sized enterprises in Beijing had to send chips to southern regions for testing, which incurred costs and delayed the R&D process by several days; the new laboratory significantly improves R&D efficiency by allowing local testing [1] - The primary investment in chip design R&D is in human resources, and by saving time in the development process, the new facilities help companies reduce costs [1]

Core Points - Zhongguancun Development Group's subsidiary, Zhongguancun International, has signed a memorandum of cooperation with Johor Land Group from Malaysia [1] - The collaboration will focus on sharing technological innovation resources and establishing the Johor Innovation Center (JIC) [1] - The partnership aims to create a technology industry service ecosystem targeting the Johor-Singapore Economic Special Zone [1]

Core Points - The completion and acceptance of the Zhongguancun Third Primary School Yongxin Branch will provide 720 quality educational slots in the northern Haidian area, promoting balanced educational development in Haidian [1] - The school serves as an important supporting facility for the Yongfeng High-tech Industrial Base, facilitating a positive cycle of attracting talent through quality education [1] - This project is a key initiative to implement the "14th Five-Year" education layout, with plans for a group-based school model that includes resource sharing and teacher exchanges to maintain educational quality [1] - The school is currently finalizing teaching equipment and has completed pre-service training for the first batch of teachers, with classes set to officially start on September 1 [1]

2025年8月13日下午，中关村发展集团召开干部大会，宣布北京市委、市政府关于中关村发展集团主要 领导任职的决定：李妍同志任中关村发展集团股份有限公司党委书记、董事长，杨仁全同志任中关村发 展集团股份有限公司党委副书记、董事、总经理。有关市领导，市委组织部、市国资委相关领导及处室 负责人，中关村发展集团领导班子成员、总部各部门正副职和子公司主要负责人参加会议。 来源：中关村发展集团 转自：北京日报客户端 中关村发展集团召开干部大会宣布主要领导任职决定 ...

Group 1 - The company held an investor relations event on August 13, attracting major institutions like Tianfeng Securities and Caitong Fund, where executives detailed the company's product layout and answered questions [1] - The focus of the event included the company's layout in narcotic drugs, market prospects for existing products, and exploration results in cutting-edge fields like mRNA [1] Group 2 - The company has accelerated its narcotic drug layout, with the sublingual tablet of dihydroetorphine hydrochloride being a key product, showing high growth potential [2] - The company has accumulated extensive experience in abuse-resistant sustained-release formulations, which are applied in multiple product developments [2] - The strict regulation of narcotic drugs creates a unique competitive barrier for companies like the company, which is one of the few manufacturers in this field [3] Group 3 - The company has identified significant market opportunities for its dihydroetorphine hydrochloride injection, projecting a 742.22% year-on-year revenue growth for 2024 [3] - The company is the only domestic pharmaceutical enterprise with integrated advantages in raw materials and formulations for dihydroetorphine hydrochloride [3] - The company has established partnerships with other formulation companies to enhance its market position in the raw material market [3] Group 4 - The company is also enhancing its narcotic drug portfolio, with the recent approval of a generic version of tramadol injection, strengthening its market competitiveness [4] Group 5 - The company's mature products, such as bisoprolol fumarate and benidipine hydrochloride, remain important revenue pillars, with the latter capturing a 55% market share in 2022 [5] - The new collection rules for centralized procurement allow for more competitive pricing strategies, which may benefit the company's main products [5] - The company is actively expanding its research and development, including studies on new indications for existing products [6] Group 6 - The company is exploring the mRNA vaccine field, with its self-built platform showing promising results in antigen design and thermal stability [6] - The company aims to establish itself as an "innovative pharmaceutical group" through continuous improvement in its narcotic drug matrix and mRNA vaccine exploration [6]

中关村发布公告称，2025年8月13日，中关村接受天风证券等投资者调研，公司副总裁范秀君、副总裁 兼董事会秘书黄志宇、证券事务代表胡秀梅参与接待，并回答了投资者提出的问题。 （文章来源：每日经济新闻） ...

证券代码：000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2025-003 投资者关系 活动类别 特定对象调研分析师会议 媒体采访 业绩说明会 新闻发布会路演活动 现场参观 其他 活动参与人员 天风证券 财通基金 周海涛 张 胤 时间 2025 年 8 月 13 日 地点 北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层公司会议室 形式 线上结合线下（公司会议室） 上市公司接待 人员姓名 副总裁：范秀君 副总裁兼董事会秘书：黄志宇 证券事务代表：胡秀梅 交流内容及具 体问答记录 一、盐酸二氢埃托啡的镇痛机制与传统类鸦片药物（如芬太尼）相比 是否更具靶向性？公司是否掌握其缓释或改良型制剂技术？ 答：盐酸二氢埃托啡与芬太尼类药物同属于强效阿片类镇痛药，通过 激活中枢神经系统内的μ 阿片受体，阻断痛觉信号传递；盐酸二氢埃托啡 对阿片受体的亲和力远高于芬太尼。 缓释或改良制剂的技术不是针对单一品种的，而是一个通用型的技术 应用于不同的品种上。北京华素制药股份有限公司研发中心具备常规缓释 及防滥用缓释制剂相关经验和技术。 1 答：镇痛药的成瘾和滥用是药物本身与机 ...

Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000931 证券简称：中关村 公告编号：2025-087 北京中关村科技发展（控股）股份 有限公司关于下属公司多多药业盐酸 曲马多注射液通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于2024年7月披露《关于下属公司多多 药业盐酸曲马多注射液一致性评价申报收到国家药品监督管理局〈受理通知书〉的公告》（公告编号： 2024-058）。 近日，公司下属公司多多药业有限公司（以下简称：多多药业）收到国家药品监督管理局核准签发的 《药品补充申请批准通知书》（通知书编号：2025B03681），获悉，多多药业生产的"盐酸曲马多注射 液"（规格：2ml:100mg）通过了仿制药质量和疗效一致性评价。现将具体情况公告如下： 一、批件主要内容 药品名称：盐酸曲马多注射液 剂型：注射剂 规格：2ml:100mg 注册分类：化学药品 受理号：CYHB2450385 通知书编号：2025B03681 上市许可持有人、生产企业：多多药业有限公司 ...